Higher Serum Cholesterol Levels Are Associated With Reduced Systemic Inflammation and Mortality During Tuberculosis Treatment Independent of Body Mass Index

Vignesh Chidambaram 1, Lucas Zhou 1, Jennie Ruelas Castillo 1, Amudha Kumar 2, Samuel K. Ayeh 1, Akshay Gupte 1, Jann-Yuan Wang 3 and Petros C. Karakousis 1, 4

1 Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States, 2 Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States, 3 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 4 Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States

Background: Lipids play a central role in the pathogenesis of tuberculosis (TB). The effect of serum lipid levels on TB treatment (ATT) outcomes and their association with serum inflammatory markers have not yet been characterized.

Methods: Our retrospective cohort study on drug-susceptible TB patients, at the National Taiwan University Hospital, assessed the association of baseline serum lipid levels such as low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC) and triglycerides (TG) with all-cause and infection-related mortality during first 9 months of ATT and baseline inflammatory markers namely C-reactive protein (CRP), total leukocyte count (WBC), and neutrophil-lymphocyte ratio (NL ratio).

Results: Among 514 patients, 129 (26.6%) died due to any-cause and 72 (14.0%) died of infection. Multivariable Cox-regression showed a lower adjusted hazard ratio (aHR) of all-cause mortality in the 3rd tertiles of HDL (aHR 0.17, 95% CI 0.07–0.44) and TC (aHR 0.30, 95% CI 0.14–0.65), and lower infection-related mortality in the 3rd tertile of HDL (aHR 0.30, 95% CI 0.14–0.65) and TC (aHR 0.30, 95% CI 0.14–0.65) compared to the 1st tertile. The 3rd tertiles of LDL and TG showed no association in multivariable analysis. Similarly, 3rd tertiles of HDL and TC had lower levels of baseline inflammatory markers such as CRP, WBC, and NL ratio using linear regression analysis. Body mass index (BMI) did not show evidence of confounding or effect modification.

Conclusions: Higher baseline serum cholesterol levels were associated with lower hazards of all-cause and infection-related mortality and lower levels of inflammatory markers in TB patients. BMI did not modify or confound this association.

Keywords: LDL-cholesterol, HDL-cholesterol, inflammation, BMI, effect modification
INTRODUCTION

Tuberculosis (TB) is an infectious disease with a high morbidity and mortality (1). Patients with TB have an increased incidence of cardiovascular (2) and cerebrovascular disease (3). Lipids play a central role in the pathogenesis of both TB and atherosclerotic vascular disease (4, 5). However, the effect of serum lipid levels on anti-tuberculosis treatment (ATT) outcomes is not yet characterized.

Studies have shown that TB patients have lower serum cholesterol levels compared to uninfected individuals (6–8). Sputum smear positivity for Mycobacterium tuberculosis (Mtbc) was associated with lower serum levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol (TC) (7). Similarly, lower levels of LDL, HDL, and TC correlated with more radiologically extensive TB disease in the lungs (7, 8). Interestingly, this pattern also holds true for the association between lipid levels and community-acquired pneumonia (7). Lower lipid levels have also been linked to higher inflammation in critically ill patients following sepsis (9), pneumonia (10), and surgery (11). Whether inflammation plays an important role in the association between lipid levels and TB outcomes is unclear.

Low body mass index (BMI), an objective marker of low nutritional status in adults, is associated with increased mortality in TB patients (12, 13). Though serum lipid levels are directly related to BMI in the under-weight and normal-weight categories, there is an inverse association with higher BMI, resulting in an inverted U-shaped relationship between these two markers (14). Thus, it becomes important to assess whether nutritional status, as suggested by BMI, confounds, or modifies the association between serum lipid levels and inflammation, and mortality in TB.

We carried out a retrospective cohort study on pulmonary TB patients receiving standard antitubercular treatment to assess the association between serum lipid levels and all-cause and infection-related mortality during 9 months of ATT initiation. We also studied the association of lipid levels with baseline serum markers of systemic inflammation at TB diagnosis.

METHODS

Design and Study Population

In our retrospective cohort on drug-susceptible TB patients (age >18 years), we used the National Taiwan University Hospital (NTUH) database from 2000 to 2016 (15, 16). TB diagnosis was confirmed by culture-based detection using MGIT-960 and Lowenstein-Jensen medium. Most patients were treated on an outpatient basis according to ATS guidelines (17). We included patients who were tested for at least one of the following serum lipid levels: LDL, HDL, TC, or triglycerides (TG), with no specific exclusion criteria. We collected baseline demographic data, such as age, sex, and comorbidities, including diabetes mellitus, hypertension, coronary artery disease, heart failure, transplantation (both solid organ and bone marrow transplantation), smoking, and alcohol use disorder. BMI at TB diagnosis was calculated as weight (kg) divided by the square of the height (m²). Data on baseline TB characteristics, such as sputum smear for acid-fast bacilli (AFB) grading (0 to 4+), prior history of TB, and presence of cavitary disease on chest radiography, were obtained. Charlson comorbidity index (CCI) was calculated from the variables obtained from the database (18). The study was approved by the institutional review boards at Johns Hopkins University and NTUH.

Exposures

The exposures assessed in our study were serum lipids, namely LDL, HDL, TC, and TG. Patients were categorized into three groups based on tertiles of the baseline lipid levels, separately for each of the above-mentioned lipids. Baseline lipid levels were defined as a test performed anytime between 1 month before and 1 month after TB diagnosis.

Inflammatory Markers

Serum inflammatory markers, namely C-reactive protein (CRP) (mg/dL), erythrocyte sedimentation rate (ESR) (mm/hr), total leukocyte count (WBC) (× 10⁹/µL) and neutrophil-lymphocyte ratio (NL ratio) at baseline were documented. Any test result for the inflammatory markers within 30 days of TB diagnosis was considered as baseline.

Outcomes

The primary outcomes evaluated were all-cause and infection-related mortality during the first 9 months of ATT. The latter was a composite outcome of death due to TB, pneumonia, or sepsis.

Statistical Analysis

Patient characteristics stratified by tertiles of the baseline serum lipid levels were compared using ANOVA for normally distributed data and Kruskal-Wallis test for non-normally distributed data, and Chi-square test for categorical variables. Kaplan-Meier and Cox proportional hazards methods were used to measure the association between the lipid tertiles and all-cause and infection-related mortality in separate models. Person-time at risk of outcome, for each of the lipid tertiles, was calculated from the time of ATT initiation until 9 months, or loss to follow-up or death, whichever occurred first. Point of loss to follow-up was defined as the last study visit prior to 9 months. Potential confounders for the multivariable analyses were identified by literature review and by exploratory univariable data analysis at p < 0.05 significance. Confounding factors that are components of the CCI were not adjusted for separately if CCI was included in the multivariable model. We performed sensitivity analyses after excluding patients who died within the first month of ATT since the definition for "baseline lipid levels" included up to 1 month after TB diagnosis. Sensitivity analysis was also performed using the exposure defined as mean value of all available lipid

Abbreviations: TB, tuberculosis; MTB, mycobacterium tuberculosis (organism); NTUH, National Taiwan University Hospital; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, total leukocyte count; NL ratio, neutrophil-lymphocyte ratio; ESR, erythrocyte sedimentation rate; ATT, TB treatment; BMI, body mass index; RA, rheumatoid arthritis; ABC, ATP- binding cassette protein; CKD, chronic kidney disease; RERI, relative excess of risk index; ANOVA, analysis of variance (Statistical test).
## TABLE 1 | Patient characteristics based on tertiles of baseline LDL and HDL levels.

| Study characteristics | Measure | All patients \( (N = 514) \) | LDL | HDL |
|-----------------------|---------|--------------------------------|-----|-----|
|                       |         | LDL tertile 1 \((n = 92)\) | LDL tertile 2 \((n = 90)\) | LDL tertile 3 \((n = 88)\) | p-value | HDL tertile 1 \((n = 83)\) | HDL tertile 2 \((n = 86)\) | HDL tertile 3 \((n = 80)\) | p-value |
| Age (years)           | Median (IQR) | 69.8 (53.9–78.8) | 70.8 (52.9–77.7) | 71.4 (51.1–77.9) | 68.4 (56.9–76.9) | 0.879 | 71.8 (53.2–77.8) | 70.6 (56.7–78.2) | 68.6 (55.3–76.3) | 0.581 |
| Male Sex              | No (%)  | 384 (74.7%) | 65 (70.7%) | 72 (80%) | 66 (75%) | 0.344 | 74 (81.3%) | 56 (71.8%) | 56 (70%) | 0.183 |
| BMI                   | Mean (SD) | 21.4 (3.7) | 19.9 (3.7) | 22.5 (4.3) | 22.4 (3.1) | <0.001 | 20.6 (3.8) | 22.4 (3.6) | 21.6 (3.7) | 0.024 |
| Initial AFB smear positivity | No (%)  | 221 (43.2%) | 43 (46.7%) | 43 (48.3%) | 39 (44.8%) | 0.898 | 48 (53.3%) | 35 (44.9%) | 34 (43.0%) | 0.355 |
| Initial AFB smear grade | Median (IQR) | 0 (0–2) | 0 (0–2) | 0 (0–2) | 0 (0–2) | 0.816 | 1 (0–2) | 0 (0–2) | 0 (0–2) | 0.619 |
| Prior TB              | No (%)  | 19 (7.2%) | 5 (10.2%) | 2 (4.2%) | 3 (7.9%) | 0.520 | 5 (10.2%) | 2 (4.2%) | 3 (7.9%) | 0.520 |
| Cavitory disease      | No (%)  | 72 (14.0%) | 13 (14.1%) | 11 (12.2%) | 17 (19.3%) | 0.395 | 6 (12.2%) | 0 (0%) | 3 (8.1%) | 0.090 |
| Smoking               | No (%)  | 117 (43.4%) | 32 (48.5%) | 31 (43.1%) | 42 (51.9%) | 0.551 | 38 (58.5%) | 31 (50.8%) | 30 (41.1%) | 0.123 |
| Alcoholism            | No (%)  | 14 (2.7%) | 1 (1.1%) | 2 (2.2%) | 2 (2.3%) | 0.799 | 4 (4.4%) | 1 (1.3%) | 0 (0%) | 0.106 |
| DM                    | No (%)  | 141 (27.4%) | 25 (27.2%) | 30 (33.3%) | 35 (39.7%) | 0.201 | 25 (27.5%) | 26 (33.3%) | 26 (32.5%) | 0.666 |
| HTN                   | No (%)  | 263 (51.4%) | 51 (55.4%) | 45 (50.0%) | 46 (52.3%) | 0.762 | 50 (54.9%) | 38 (48.7%) | 41 (51.3%) | 0.716 |
| Cancer                | No (%)  | 81 (15.8%) | 15 (16.3%) | 11 (12.2%) | 8 (9.1%) | 0.342 | 8 (8.8%) | 9 (11.5%) | 15 (18.8%) | 0.139 |
| CKD Stage ≥3          | No (%)  | 37 (7.2%) | 13 (14.1%) | 4 (4.4%) | 2 (2.7%) | 0.004 | 8 (8.8%) | 6 (7.7%) | 4 (5.0%) | 0.622 |
| Asthma                | No (%)  | 21 (4.1%) | 4 (4.4%) | 1 (1.1%) | 7 (7.9%) | 0.086 | 4 (4.4%) | 2 (2.6%) | 5 (6.3%) | 0.530 |
| COPD                  | No (%)  | 88 (17.1%) | 11 (11.9%) | 19 (21.1%) | 17 (19.3%) | 0.225 | 10 (10.9%) | 18 (23.1%) | 13 (16.3%) | 0.107 |
| Bronchiectasis        | No (%)  | 16 (3.1%) | 2 (2.2%) | 2 (2.2%) | 3 (3.4%) | 0.842 | 2 (2.2%) | 2 (2.6%) | 3 (3.8%) | 0.818 |
| Pneumonocosis         | No (%)  | 4 (0.8%) | 1 (1.1%) | 0 (0%) | 0 (0%) | 0.614 | 0 (0%) | 1 (1.3%) | 0 (0%) | 0.333 |
| Autoimmune disease    | No (%)  | 25 (4.9%) | 2 (2.2%) | 3 (3.3%) | 4 (4.6%) | 0.675 | 3 (3.3%) | 4 (5.1%) | 1 (1.3%) | 0.384 |
| Liver cirhosis        | No (%)  | 13 (2.5%) | 4 (4.4%) | 2 (2.2%) | 0 (0%) | 0.141 | 3 (3.3%) | 2 (2.6%) | 0 (0%) | 0.282 |
| History of transplant | No (%)  | 16 (3.1%) | 5 (5.4%) | 5 (5.6%) | 4 (4.6%) | 0.946 | 2 (2.2%) | 1 (1.3%) | 10 (12.5%) | 0.002 |
| HIV                   | No (%)  | 21 (4.1%) | 9 (9.8%) | 6 (6.7%) | 1 (1.1%) | 0.046 | 10 (10.9%) | 2 (2.6%) | 3 (3.8%) | 0.042 |
| CAD                   | No (%)  | 72 (14.0%) | 14 (15.2%) | 19 (21.1%) | 11 (12.5%) | 0.281 | 13 (14.3%) | 9 (11.5%) | 15 (18.8%) | 0.436 |
| AMI                   | No (%)  | 29 (5.6%) | 6 (6.5%) | 7 (12.5%) | 3 (5.4%) | 0.411 | 5 (5.5%) | 6 (7.7%) | 5 (6.3%) | 0.842 |
| CHF                   | No (%)  | 35 (6.6%) | 9 (15.5%) | 9 (10.0%) | 3 (3.4%) | 0.211 | 9 (9.9%) | 6 (7.7%) | 7 (8.8%) | 0.881 |
| CVA                   | No (%)  | 33 (6.4%) | 9 (9.8%) | 6 (6.7%) | 4 (4.6%) | 0.384 | 10 (10.9%) | 5 (6.4%) | 5 (6.5%) | 0.398 |
|CCI                   | Mean (SD) | 4.4 (2.6) | 5.2 (2.9) | 4.9 (2.6) | 4.1 (2.0) | 0.029 | 4.7 (2.5) | 4.6 (2.6) | 4.5 (2.5) | 0.818 |
| Metformin use         | No (%)  | 81 (15.8%) | 11 (11.9%) | 20 (22.2%) | 20 (22.7%) | 0.112 | 10 (10.9%) | 17 (21.8%) | 14 (17.5%) | 0.161 |
| Statin use            | No (%)  | 61 (11.9%) | 12 (13.0%) | 19 (21.1%) | 14 (15.9%) | 0.335 | 10 (10.9%) | 11 (14.1%) | 16 (20.0%) | 0.249 |
| CCB use               | No (%)  | 117 (22.8%) | 26 (28.3%) | 20 (22.2%) | 19 (21.6%) | 0.510 | 23 (25.3%) | 17 (21.8%) | 21 (26.3%) | 0.790 |

AFB, acid–fast bacilli; AMI, acute myocardial infarction; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CCI, charlson comorbidity index; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, diabetes mellitus; HDL, high density lipoprotein cholesterol; HIV, human immunodeficiency virus; HTN, hypertension; IQR, interquartile range; LDL, low density lipoprotein cholesterol; PVD, peripheral vascular disease; SD, standard deviation.
| Study Characteristics | Measure                      | Total Cholesterol (TC) | Triglycerides (TG) |
|-----------------------|------------------------------|------------------------|--------------------|
|                       | TC tertile 1 ($n = 146$)     | TC tertile 2 ($n = 140$)| TC tertile 3 ($n = 143$) | $p$-value | TG tertile 1 ($n = 166$) | TG tertile 2 ($n = 166$) | TG tertile 3 ($n = 163$) | $p$-value |
| Age (years)           | Median (IQR)                 | 72.6 (54.1–81.2)       | 69.4 (53.4–78.7)   | 65.9 (51.9–76.4) | 0.067 | 71.8 (54.1–81.5)       | 71.5 (56.7–79.2)       | 64.5 (51.9–76.8) | 0.044    |
| Male Sex              | No (%)                       | 109 (74.7%)            | 99 (70.7%)         | 107 (74.8%)      | 0.676 | 132 (79.5%)            | 119 (71.7%)            | 119 (73.0%)      | 0.214    |
| BMI                   | Mean (SD)                    | 19.9 (3.2)             | 22.3 (3.9)         | 22.2 (3.5)       | <0.001 | 20.5 (3.5)             | 21.6 (3.8)             | 22.1 (3.8)       | 0.002    |
| Initial AFB smear positivity | No (%)                     | 62 (42.5%)           | 64 (46.0%)         | 64 (45.1%)       | 0.820 | 63 (38.2%)            | 65 (39.2%)            | 79 (48.8%)       | 0.101    |
| Prior TB              | No (%)                       | 11 (12.6%)             | 5 (7.3%)           | 3 (4.6%)         | 0.186 | 6 (6.9%)               | 5 (5.6%)              | 5 (6.3%)         | 0.940    |
| Smoking               | No (%)                       | 52 (52.0%)             | 45 (38.5%)         | 47 (38.5%)       | 0.072 | 55 (41.4%)             | 56 (41.5%)            | 63 (50%)         | 0.278    |
| Alcoholism            | No (%)                       | 3 (2.1%)               | 4 (2.9%)           | 5 (3.5%)        | 0.758 | 3 (1.8%)               | 2 (1.2%)              | 9 (5.5%)         | 0.038    |
| DM                    | No (%)                       | 31 (12.2%)             | 50 (35.7%)         | 40 (27.9%)       | 0.025 | 31 (18.7%)             | 47 (28.3%)            | 58 (35.6%)       | 0.003    |
| HTN                   | No (%)                       | 72 (49.3%)             | 61 (43.6%)         | 78 (54.6%)       | 0.182 | 68 (40.9%)             | 66 (39.8%)            | 76 (46.6%)       | 0.405    |
| Cancer                | No (%)                       | 18 (12.3%)             | 21 (15%)           | 22 (15.4%)       | 0.720 | 34 (20.5%)             | 22 (13.3%)            | 20 (12.3%)       | 0.077    |
| CKD Stage ≥ 3         | No (%)                       | 14 (9.6%)              | 7 (5%)             | 8 (5.6%)         | 0.240 | 14 (8.4%)              | 6 (3.6%)              | 16 (9.8%)        | 0.075    |
| Asthma                | No (%)                       | 4 (2.7%)               | 2 (1.4%)           | 10 (7%)         | 0.035 | 5 (3.0%)               | 8 (4.8%)              | 8 (4.9%)         | 0.627    |
| COPD                  | No (%)                       | 22 (15.1%)             | 23 (16.4%)         | 29 (20.3%)       | 0.479 | 26 (15.7%)             | 32 (19.3%)            | 25 (15.3%)       | 0.567    |
| Bronchiectasis        | No (%)                       | 5 (3.4%)               | 4 (2.9%)           | 5 (3.5%)        | 0.947 | 2 (1.2%)               | 10 (6.0%)             | 3 (1.8%)         | 0.021    |
| Pneumoconiosis        | No (%)                       | 1 (0.7%)               | 1 (0.7%)           | 2 (1.4%)        | 0.777 | 0 (0%)                 | 2 (1.2%)              | 2 (1.2%)         | 0.361    |
| Autoimmune disease    | No (%)                       | 4 (2.7%)               | 3 (2.1%)           | 5 (3.6%)        | 0.238 | 6 (3.6%)               | 5 (3.0%)              | 12 (7.4%)        | 0.128    |
| Liver cirrhosis       | No (%)                       | 7 (4.8%)               | 3 (2.1%)           | 2 (1.4%)        | 0.183 | 8 (4.8%)               | 4 (2.4%)              | 1 (0.6%)         | 0.057    |
| History of transplant | No (%)                       | 3 (2.3%)               | 8 (7.2%)           | 4 (4.1%)        | 0.188 | 4 (2.4%)               | 7 (4.2%)              | 5 (3.1%)         | 0.642    |
| HIV                   | No (%)                       | 9 (6.8%)               | 3 (2.7%)           | 3 (3.1%)        | 0.228 | 2 (1.2%)               | 10 (6.0%)             | 8 (4.9%)         | 0.067    |
| CAD                   | No (%)                       | 18 (13.5%)             | 22 (19.8%)         | 12 (12.2%)       | 0.248 | 20 (12.1%)             | 29 (17.5%)            | 20 (12.3%)       | 0.273    |
| AMI                   | No (%)                       | 6 (4.1%)               | 10 (7.1%)          | 4 (2.8%)        | 0.206 | 7 (4.2%)               | 11 (6.6%)             | 9 (5.5%)         | 0.626    |
| CHF                   | No (%)                       | 12 (8.2%)              | 9 (6.4%)           | 6 (4.2%)        | 0.370 | 10 (6.0%)              | 14 (8.4%)             | 8 (4.9%)         | 0.413    |
| CVA                   | No (%)                       | 12 (8.2%)              | 6 (4.3%)           | 5 (3.5%)        | 0.161 | 13 (7.8%)              | 11 (6.6%)             | 8 (4.9%)         | 0.566    |
| CCI                   | No (%)                       | 4.6 (2.7)              | 4.5 (2.7)          | 3.9 (2.2)       | 0.069 | 4.4 (2.9)              | 4.6 (2.5)             | 4.3 (2.5)        | 0.457    |
| Metformin use         | No (%)                       | 16 (10.9%)             | 21 (15.0%)         | 28 (19.6%)       | 0.124 | 14 (8.4%)              | 27 (16.3%)            | 36 (22.1%)       | 0.003    |
| Statin use            | No (%)                       | 13 (8.9%)              | 18 (12.9%)         | 24 (16.8%)       | 0.134 | 11 (6.6%)              | 20 (12.1%)            | 26 (15.9%)       | 0.029    |
| CCB use               | No (%)                       | 32 (21.9%)             | 23 (16.4%)         | 36 (25.2%)       | 0.192 | 35 (21.1%)             | 37 (23.2%)            | 43 (26.4%)       | 0.492    |

AFB, acid-fast bacilli; AMI, acute myocardial infarction; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CCI, chartson comorbidity index; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, diabetes mellitus; HIV, human immunodeficiency virus; HTN, hypertension; IQR, interquartile range; PVD, peripheral vascular disease; SD, standard deviation; TC, total cholesterol; TG, triglycerides.
Association of baseline serum lipid levels and inflammatory markers, namely CRP, ESR, WBC and NL ratio, were analyzed using univariable and multivariable linear regression analyses. We performed sensitivity analysis by assessing the association of baseline lipid levels and inflammatory markers obtained up to day 15 of ATT to account for the possibility of a rapid decrease in inflammation after ATT initiation.

The association of tertiles of baseline lipid levels with BMI was assessed using linear regression analysis. Effect modification by BMI at different cut-offs, on the association between lipid levels and mortality or elevated inflammatory markers were evaluated using the Cox and logistic regression models, respectively, by stratification, multiplicative and additive interactions. Relative excess of risk index (RERI) was used to assess the magnitude and the significance of the additive effect modification using the “ic package” in STATA. All analyses were performed using Stata, version 16.0 IC (StataCorp LP, College Station, TX).

RESULTS
Baseline Characteristics Stratified by Lipid Tertiles
In our cohort, among 2,894 patients with drug-sensitive pulmonary TB, 514 patients with at least one serum lipid measurement available at baseline were included (Supplementary Figure 1). The median (IQR) range was 69.8 years (53.9–78.8), and 384 patients (74.7%) were male (Table 1). Forty-three percent of this population were ever-smokers, and 2.7% reported alcohol use disorder. At baseline, 221 patients (43.2%) had positive sputum AFB smears and 14% patients had cavitation on chest imaging. Nineteen patients (7.2%) had a past history of TB.

Patient characteristics stratified by tertiles of baseline serum lipid levels are shown in Tables 1, 2. Patients in the lowest LDL tertile had higher proportions of CKD Stage 3–5 (14.1 vs. 4.4 vs. 2.2%, p-value = 0.004) and higher mean values of CCI (5.2 vs. 4.9 vs. 4.1, p-value = 0.029). Patients in the lowest HDL tertile had a higher HIV proportion compared to the higher tertiles (10.9 vs. 2.6 vs. 3.8%, p-value = 0.004). There was a lower proportion
### TABLE 3 | Association of serum lipid levels with all-cause and infection-related mortality by Cox regression analysis.

| Type of lipid | Total patient (N) | 9-month all-cause mortality | 9-month Infection related mortality |
|---------------|-------------------|-----------------------------|-----------------------------------|
|               |                  | n (%) | Unadjusted HR (95%CI) | p-value | Adjusted HR | 95%CI | p-value | n (%) | Unadjusted HR (95%CI) | p-value | Adjusted HR | 95%CI | p-value |
| LDL tertiles  |                   |       |                     |         |             |       |         |       |                     |         |             |       |         |
| 1st           | 92                | 32 (37.2%) | Ref | – | – | – | – | 19 | Ref | – | – | – | – |
| 2nd           | 90                | 21 (24.1%) | 0.64 | 0.37–1.17 | 0.117 | 1.03 | 0.50–2.12 | 0.933 | 13 | 0.68 | 0.34–1.38 | 0.284 | 1.36 | 0.54–3.41 | 0.510 |
| 3rd           | 88                | 13 (19.7%) | 0.38 | 0.19–0.72 | 0.003 | 0.60 | 0.24–1.49 | 0.273 | 4 (4.7%) | 0.19 | 0.07–0.59 | 0.003 | 0.42 | 0.11–1.67 | 0.218 |
| HDL tertiles  |                   |       |                     |         |             |       |         |       |                     |         |             |       |         |
| 1st           | 83                | 32 (37.7%) | Ref | – | – | – | – | 20 | Ref | – | – | – | – |
| 2nd           | 86                | 21 (27.6%) | 0.71 | 0.41–1.23 | 0.230 | 0.40 | 0.19–0.85 | 0.017 | 12 | 0.66 | 0.32–1.35 | 0.259 | 0.43 | 0.16–1.19 | 0.106 |
| 3rd           | 80                | 9 (11.7%) | 0.27 | 0.13–0.57 | 0.001 | 0.17 | 0.07–0.44 | <0.001 | 3 (3.9%) | 0.15 | 0.04–0.50 | 0.002 | 0.13 | 0.03–0.53 | 0.004 |
| TC tertiles   |                   |       |                     |         |             |       |         |       |                     |         |             |       |         |
| 1st           | 146               | 52 (38.8%) | Ref | – | – | – | – | 34 | Ref | – | – | – | – |
| 2nd           | 140               | 25 (18.4%) | 0.44 | 0.28–0.72 | 0.001 | 0.54 | 0.29–0.99 | 0.049 | 11 | 0.31 | 0.16–0.61 | 0.001 | 0.35 | 0.15–0.86 | 0.021 |
| 3rd           | 143               | 12 (8.8%) | 0.19 | 0.11–0.37 | <0.001 | 0.30 | 0.14–0.65 | 0.003 | 6 (4.4%) | 0.16 | 0.07–0.37 | <0.001 | 0.26 | 0.09–0.72 | 0.009 |
| TG tertiles   |                   |       |                     |         |             |       |         |       |                     |         |             |       |         |
| 1st           | 166               | 58 (38.2%) | Ref | – | – | – | – | 30 | Ref | – | – | – | – |
| 2nd           | 166               | 30 (18.9%) | 0.47 | 0.30–0.73 | 0.001 | 0.58 | 0.33–1.01 | 0.054 | 18 | 0.56 | 0.31–1.01 | 0.054 | 0.71 | 0.35–1.41 | 0.322 |
| 3rd           | 165               | 39 (25.0%) | 0.65 | 0.43–0.97 | 0.037 | 1.08 | 0.65–1.81 | 0.765 | 23 | 0.75 | 0.44–1.30 | 0.311 | 1.14 | 0.58–2.24 | 0.711 |

LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; HR, hazard ratio.

*Adjusted for age; sex; BMI, body mass index; CCI, charlson comorbidity index; transplantation; alcoholism; smoking; initial AFB smear; presence of cavitary disease; metformin, statin, and calcium channel blocker use.

Ref, Reference group for the cox-regression analysis among the three tertiles.
FIGURE 2 | Kaplan Meier analysis of the association of baseline serum lipid level tertile with all-cause mortality. (A) Low density lipoprotein (LDL); (B) High density lipoprotein (HDL); (C) Total cholesterol (TC); (D) Triglycerides (TG). TB, tuberculosis.

of diabetes mellitus in the lowest tertiles of TC (12.2 vs. 35.7 vs. 27.9%, p-value = 0.025) and TG (18.7 vs. 28.3 vs. 35.6%, p-value = 0.003) (Tables 1, 2). Inflammatory markers, namely CRP, ESR, WBC and NL ratio, were available for 239 (46.4%), 27 (5.3%), 365 (71.0%) and 343 (66.7%) patients, respectively.

BMI was significantly higher in the higher tertiles for each lipid (Figure 1). The association of tertiles of lipid levels with BMI using linear regression analysis is shown in Supplementary Table 1.

Outcomes
Among 514 patients, 129 (26.6%) died due to any cause during a median follow up of 270 (IQR 206–270) days (Supplementary Table 2). A total of 72/514 patients (14.0%) died of infection-related causes, constituting 55.8% (72/129 patients) of all deaths during the first 9 months of TB treatment. Of this group, 4 patients (5.5%) died due to TB-related causes, 21 patients (29.2%) due to pneumonia and 45 patients (62.5%) due to sepsis. All-cause and infection-related mortality stratified by lipid levels are shown in Table 3.

Effect of Serum Lipid Levels on 9-Month All-Cause Mortality and Infection-Related Mortality
During the first 9 months of ATT initiation, there was a lower hazard of all-cause mortality in univariable Cox regression for the 3rd tertiles of LDL (HR 0.38, 95% CI 0.19–0.72), HDL (HR 0.27, 95% CI 0.13–0.57), TC (HR 0.19, 95% CI 0.11–0.37) and TG (HR 0.65, 0.43–0.97) (Table 3). The log-rank test of the Kaplan-Meier analysis showed that patients classified in the 3rd tertiles of LDL, HDL, TC and TG had significantly longer survival compared to the other tertiles (Figure 2; p < 0.001). After adjusting for confounders, namely age, sex, BMI, CCI, transplantation, alcohol use disorder, smoking, initial AFB smear positivity, presence of cavitations, metformin, statin, and calcium channel blocker use for each of the serum lipid levels, lower hazards of all-cause mortality were only noted in the 2nd and 3rd tertiles of HDL and TC compared to the 1st tertile (Table 3). Serum LDL and TG did not show a significant association with all-cause mortality in the multivariable analysis.

There was lower infection-related mortality in the univariable Cox regression analysis in the 3rd tertile of HDL and 2nd and
3rd tertiles of LDL and TC compared to the 1st tertiles of the corresponding lipids (Table 3). Kaplan-Meier analysis showed that patients in the 3rd tertiles of LDL, HDL, and TC significantly longer survival from infection-related mortality compared to the 1st and 2nd tertiles (Figure 3; \( p < 0.001 \)). After adjusting for confounders, lower hazards of infection-related mortality were noted in the 3rd tertile of HDL and the 2nd and 3rd tertiles of TC (Table 3). Serum LDL and TG showed no association with infection-related mortality in the multivariable analysis.

**Sensitivity Analysis**

Sensitivity analysis after excluding patients who died within the first month of ATT initiation showed a similar lower all-cause and infection-related mortality for the 3rd tertile of HDL and TC but not LDL (Supplementary Table 3). The 2nd tertile of TG showed significantly lower all-cause mortality compared to the 1st and 3rd tertiles. A similar association was noted for infection-related mortality but was non-significant. Similar findings were noted during sensitivity analysis using mean lipid levels during TB treatment (Supplementary Table 4).

**Effect of Serum Lipid Levels on Baseline Inflammatory Markers**

The association of serum lipid levels with serum inflammatory markers are shown in Table 4 and Figure 4. The 3rd tertiles of HDL and TC were associated with significantly lower levels of CRP, WBC, and NL ratio, while the 3rd tertile of LDL and 2nd tertile of TG were associated only with lower CRP levels in the multivariable model (Table 4). When lipid levels were considered as continuous variables, each 10 mg/dL increase in baseline serum HDL and TC was associated with lower CRP levels by 0.79 mg/dL (\( p = 0.007 \)) and 0.15 mg/dL (\( p = 0.026 \)), respectively, in multivariable linear regression analysis (Supplementary Table 5). The analysis for ESR was not performed because of a very low proportion of patients (2.3%) with these test results. Multivariable linear regression models showed a consistent inverse relationship between elevated HDL and TC levels and WBC and NL ratio (Table 4). LDL levels were not associated with lower WBC or NL ratios in the multivariable models. The 2nd tertile of TG levels showed lower levels of CRP compared to the 1st tertile. However, there was no association between TG levels and WBC, or NL ratio.
TABLE 4

| Type of lipid | CRP (mg/dL) | Total Leukocyte count ($\times 10^{3}$/L) | NL ratio | p-value | Mean (SD) | B (SE) | p-value | Multivariable B (SE) | p-value |
|--------------|-------------|----------------------------------------|----------|---------|-----------|--------|---------|---------------------|---------|
| LDL tertiles |             |                                        |          |         |           |        |         |                     |         |
| 1st          | 7.3 (4.2)   | Ref                                    |          | -       | 1.36 (0.85) | 0.113  |          | Ref                 | -       |
| 2nd          | 5.9 (4.1)   | 1.31 (0.98)                           |          | 0.002  | 1.71 (1.14) | 0.138  |          | 0.66 (0.71)        | 0.336   |
| 3rd          | 4.1 (3.4)   | 3.14 (0.95)                           |          | 0.007  | 0.66 (0.69) | 0.002  |          | 0.70 (0.42)        | 0.178   |
| HDL tertiles |             |                                        |          |         |           |        |         |                     |         |
| 1st          | 7.4 (4.3)   | Ref                                    |          | 0.336  | -1.88 (0.73) | 0.011  |          | 1.68 (0.57)        | 0.034   |
| 2nd          | 5.6 (4.4)   | -1.83 (0.91)                         |          | 0.025  | -0.81 (0.75) | 0.007  |          | 0.81 (0.75)        | 0.034   |
| 3rd          | 5.1 (4.1)   | 0.19 (0.97)                           |          | 0.008  | 0.35 (0.82) | 0.038  |          | 0.35 (0.35)        | 0.034   |
| TC tertiles  |             |                                        |          |         |           |        |         |                     |         |
| 1st          | 6.9 (4.1)   | Ref                                    |          | -       | 1.15 (0.56) | 0.003  |          | 0.27 (0.32)        | 0.003   |
| 2nd          | 5.9 (4.1)   | 1.31 (0.95)                           |          | 0.067  | 0.87 (0.89) | 0.021  |          | 0.87 (0.89)        | 0.003   |
| 3rd          | 4.3 (3.1)   | 3.14 (0.95)                           |          | 0.001  | 3.27 (1.19) | 0.006  |          | 3.27 (1.19)        | 0.006   |
| TG tertiles  |             |                                        |          |         |           |        |         |                     |         |
| 1st          | 7.1 (4.2)   | Ref                                    |          | -       | -2.73 (1.17) | 0.001  |          | -2.73 (1.17)       | 0.001   |
| 2nd          | 5.9 (4.1)   | 1.83 (0.91)                           |          | 0.001  | -2.28 (1.17) | 0.001  |          | -2.28 (1.17)       | 0.001   |
| 3rd          | 4.1 (3.4)   | -1.89 (0.98)                         |          | 0.007  | -0.39 (0.89) | 0.002  |          | -0.39 (0.89)       | 0.002   |

LDL, Low density lipoprotein cholesterol; HDL, High density lipoprotein cholesterol; TC, Total cholesterol; TG, Triglycerides; B, Linear regression co-efficient; SE, standard error; CRP, C-reactive protein; NL ratio, neutrophil-lymphocyte ratio.

#Adjusted for age; sex; BMI, body mass index; CCI, Charlson comorbidity index; transplantation; alcoholism; smoking; initial AFB smear; presence of cavitary disease; metformin, statin, and calcium channel blocker use.

Sensitivity Analysis

We performed sensitivity analyses by restricting the baseline lipid levels and inflammatory markers to the first 15 days of TB treatment and found that the 3rd tertiles of HDL were associated with lower CRP and NL ratio, while the 3rd tertile of TC was associated with lower CRP, WBC, and NL ratio in the multivariable model. The 3rd tertile of LDL and the 2nd tertile of TG were associated with non-significantly lower inflammatory markers compared to the 1st tertile in the multivariable model (Supplementary Table 6).

Test of Effect Modification by BMI on the Association of Lipid Levels With Mortality and the Level of Inflammation

Stratified analysis based on three different cut-offs of BMI (20, 21, and 22 kg/m²) were performed. The strata with high lipid levels (3rd tertile) and BMI greater than the cut-offs (20, 21, and 22 kg/m²) showed significantly lower hazard of all-cause and infection-related mortality and lower odds of elevated inflammatory markers, namely CRP > 5 mg/dL, WBC > 10 X 10³/µL, and NL ratio > 4 (Supplementary Tables 7–11). We found no evidence of effect modification for the lipid levels by BMI for the above outcomes across any of the cut-offs of BMI (Supplementary Tables 7–11).

**DISCUSSION**

In our retrospective cohort, we found that higher serum cholesterol levels were associated with lower hazards of all-cause and infection-related mortality during ATT, independent of confounding factors. While higher serum LDL showed lower hazard ratios for mortality in univariable Cox regression alone, higher serum HDL and TC showed this association in both univariable and multivariable analyses. The linear regression model demonstrated that higher levels of LDL, HDL and TC were independently associated with lower levels of inflammatory markers such as CRP, WBC, and NL ratio.

Preclinical studies have found that *Mtb* can manipulate host lipids in several ways. *Mtb* induces host lipid accumulation, primarily TG and cholesterol esters, to promote its intracellular survival, leading to the formation of lipid-laden foam cells (19, 20). In addition to serving as a nutrient reservoir for dormant *Mtb* (21), these host lipids impair the ability of macrophages to kill intracellular bacilli.

Prior literature has shown that active TB patients have decreased serum cholesterol levels (6–8). Lower serum levels of LDL, HDL and TC correlated with more extensive TB lung disease (7, 8), such as larger caseous lesions and severe fibro-encapsulation (22). Consistent with these data, lower serum levels of cholesterol have been associated with increased proportion of sputum smear positivity for *Mtb* (7, 22). Conversely, adult TB patients receiving a cholesterol-rich diet (800 mg/d cholesterol) experienced accelerated sterilization of sputum *Mtb* cultures during ATT relative to controls receiving a normal diet (250 mg/d cholesterol) (23). In our study, we found that the highest tertiles
of serum LDL, HDL and TC levels were associated with lower hazards of mortality in the first 9 months of ATT.

CRP and NL ratio are important markers of systemic inflammation in TB (24). Though correlation is demonstrated between serum cholesterol levels and systemic inflammatory markers in TB, an association after adjusting for other confounders is not established (7). We showed that among active TB patients, higher serum HDL and TC are independently associated with lower CRP, WBC, and NL ratio in both univariable and multivariable linear regression (Table 4).

The reason for the association of higher serum cholesterol with lower systemic inflammation is currently unknown. Murine models have shown that hypercholesterolemia results in a hyperinflammatory response to Mtb infection (25) and impairs host defenses against TB (26). It has been hypothesized that lower serum lipids during inflammation may be due to an acute phase response (27). Preclinical studies revealed, in response to inflammation, an increase in secretory phospholipase A2 and serum amyloid A, thereby decreasing HDL levels (28, 29). Additionally, reverse cholesterol transport mediated by ATP-binding cassette transporter (ABC) and lecithin-cholesterol acyltransferase (LCAT) are decreased during inflammation, leading to decreased HDL (30). Lower serum lipid levels are also associated with greater levels of systemic inflammation in other infections (9–11, 31–33). A similar clinical scenario has been explored in patients with rheumatoid arthritis (RA). Patients with RA had a more atherogenic lipid profile (high LDL and TC, low HDL) prior to symptom development (34), with a significant decline in lipid levels following RA development when compared to healthy controls (35). Furthermore, there was an increase in lipid levels following anti-inflammatory therapy with TNF-alpha inhibitors (36). No current evidence supports that low serum lipids predispose to greater inflammation. Thus, lower lipid levels are more likely a result, rather than a cause, of increased inflammation in TB disease.

TB patients have higher degrees of wasting, with relatively low serum levels of amino acids, cholesterol, fatty acids and phospholipid metabolites (37). Malnutrition, suggested by low BMI, is associated with an increased risk of TB (38), and with worse TB outcomes, such as mortality (13), poor sputum conversion rates (39), and greater radiographic severity (40). Additionally, higher BMI is correlated with improved survival and earlier sputum conversion (12, 13, 41). The available evidence regarding the association of BMI with the levels of inflammation in TB is unclear. Studies show that increased BMI is associated with increased (42), decreased (43) or unchanged (44) serum levels of pro-inflammatory cytokines. Though serum cholesterol and TG levels showed a direct relationship with BMI, beyond certain inflection points in BMI, the slope in the association with lipid levels decreased to a plateau. In our cohort, BMI did not significantly confound or modify the association of lipid levels with mortality or inflammation at various cut-off levels. Thus, we have demonstrated that the effect of lipid levels on the outcomes are independent of nutritional status.

Our study has several strengths. Our larger sample size with relevant data on the confounders enabled the inferences obtained in our study. Treatment options were standardized at the study center, thereby decreasing the heterogeneity in
the treatment received. We note a few limitations, including the lack of standardized periods for follow-up data on serum lipid levels, which would have enabled an assessment of trend of lipids during the course of ATT. Availability of additional lab markers, like serum albumin, would have facilitated further assessment of patients' nutritional status. We were unable to evaluate the association of lipid levels with TB-specific outcomes, such as sputum conversion and lung function from this subset of our patient cohort. Ours is a single center study with a high proportion of elderly patients, and multicenter cohorts might help to corroborate our results.

CONCLUSIONS

In summary, we demonstrated that higher serum cholesterol levels are associated with lower hazards of all-cause and infection-related mortality during ATT and lower levels of systemic inflammation at baseline, independent of BMI. There was no effect modification by BMI on the above associations. Cohort studies assessing TB incidence might enable us to determine whether lower lipid levels are the cause or the effect of severe TB disease. An improved understanding of this relationship might provide further insights into TB pathogenesis and help to risk-stratify patients based on serum lipid levels.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Tuberculosis. Available online at: https://www.who.int/news-room/factsheets/detail/tuberculosis. (accessed February 22, 2021).
2. Wongtrakul W, Charoenngam N, Ungprasert P. Tuberculosis and risk of coronary heart disease: a systematic review and meta-analysis. Indian J Tuberc. (2020) 67:182–8. doi: 10.1016/j.ijtb.2020.01.008
3. Sheu JJ, Chiou HY, Kang JH, Chen YH, Lin HC. Tuberculosis and the risk of ischemic stroke: a 3-year follow-up study. Stroke. (2010) 41:244–9. doi: 10.1161/STROKEAHA.109.567735
4. Wilburn KM, Fieweger RA, Vanderven BC. Cholesterol and fatty acids grease the wheels of mycobacterium tuberculosis pathogenesis. (2018) 76:21. doi: 10.1093/femspd/fhy021
5. Libby P, Touroux P. Pathophysiology of coronary artery disease. Circulation. (2005) 111:3481–8. doi: 10.1161/CIRCULATIONAHA.105.537875
6. Pérez-Guzmán C, Vargas MH, Salas-Márter G, Trejo-Santacruz J, Gallegos-Discua C, Flores-López F. Aportaciones originales. Rev Med Inst Mex Seguro Soc. (2008) 50:471–6.
7. Sahin F, Yildiz P. Distinctive biochemical changes in pulmonary tuberculosis and pneumonia. Arch Med Sci. (2013) 9:656–61. doi: 10.5114/ams.2013.34403
8. Deniz O, Gumus S, Yaman H, Ciftci F, Ors F, Cakir E, et al. Serum total cholesterol, HDL-C and LDL-C concentrations significantly correlate with the radiological extent of disease and the degree of smear positivity in patients with pulmonary tuberculosis. Clin Biochem. (2007) 40:162–6. doi: 10.1016/j.clinbiochem.2006.10.015
9. Volpato S, Palmieri E, Fellin R, Zuliani G. Acute phase markers are associated with reduced plasma lipid levels in a population of hospitalized elderly patients. Gerontology. (2000) 46:22–27. doi: 10.1159/000022129
10. Deniz O, Tozkoparan E, Yaman H, Cakir E, Gumus S, Ozcan O, et al. Serum HDL-C levels, log (TG/HDL-C) values and serum total cholesterol/HDL-C ratios significantly correlate with radiological extent of disease in patients with community-acquired pneumonia. Clin Biochem. (2006) 39:287–92. doi: 10.1016/j.clinbiochem.2006.01.015
11. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JCL, Sloan BJ, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med. (2001) 29:1563–8. doi: 10.1097/00003246-200108000-00011
12. Ngata N, Matsunaga K, Nakamatsu K, Kaihara Y. The relation between nutritional state of tuberculous patients admitted in tuberculous ward and their outcome at the time of discharge. Keksiku. (2009) 8:611–6.
13. Benova L, Fielding K, Greig J, Nyang’wa BT, Casas EJ, da Fonseca MS, et al. Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in myanmar and zimbabwe. PLoS ONE. (2012) 7:e35948. doi: 10.1371/journal.pone.0035948
14. Laclaustra M, Lopez-Garcia E, Civeira F, Garcia-ESquinias G, Graciani A, Guillar-Castillon P, et al. LDL cholesterol rises with BMI only in lean individuals: Cross-sectional U.S And Spanish representative data. Diab Care. (2018) 41:2195–201. doi: 10.2337/dc18-0372
15. Chidambaram V, Gupte A, Wang J-Y, Golub JE, Karakousis PC. The impact of hypertension and use of calcium channel blockers on tuberculosis treatment outcomes. Clin Infect Dis. (in press). doi: 10.10110/2020.09.012015975

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Johns Hopkins University and National Taiwan University Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

VC and PK conceived the study. J-YW collected the data. VC performed the analysis. AG guided in the analysis and the methods. VC, LZ, JR, and AK drafted the manuscript. AG, J-YW, and PK corrected the draft. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) grants UH3AI122309 and K24AI143447 to PK; and the Taiwan Centers for Disease Control grant MOHW-105-CDC-C-114-000103 to J-YW.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.696517/full#supplementary-material
16. Degner NR, Wang J-Y, Golub JE, Karakousis PC. Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment. *Clin Infect Dis.* (2018) 66:198–205. doi: 10.1093/cid/cix819

17. Nahid P, Dorman SE, Alpanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis.* (2016) 63:e147–95. doi: 10.1093/cid/ciw376

18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* (1987) 40:373–83. doi: 10.1016/0021-9681(87)90171-P

19. Jaisinghani N, Dawa S, Singh K, Nandy A, Menon D, Bhandari P, et al. Necrosis driven triglyceride synthesis primes macrophages for inflammation during mycobacterium tuberculosis infection. *Front Immunol.* (2018) 9:1490. doi: 10.3389/fimmu.2018.01490

20. Agarwal P, Combes TW, Shojaei-Moradie F, Fielding B, Gordon S, Mizrahi V, et al. Foam cells control macrophacterium tuberculosis infection. *Front Microbiol.* (2020) 11:1394. doi: 10.3389/fmicb.2020.594142

21. Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao KVS. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. *Cell Host Microbe.* (2012) 12:669–81. doi: 10.1016/j.chom.2012.09.012

22. Dong Z, Shi J, Dorhoi A, Zhang J, Soodeen-Lalloo AK, Tan WL, et al. Hemostasis and lipoprotein indices signify exacerbated lung injury in TB with diabetes comorbidity. *Chest.* (2018) 153:1187–200. doi: 10.1016/j.chest.2017.11.029

23. Pérez-Guzmán C, Vargas MH, Quiñoñez F, Bazavilvazo N, Aguilera A. A cholesterol-rich diet accelerates bacteriocidal sterilization in pulmonary tuberculosis. *Chest.* (2005) 127:643–51. doi: 10.1378/chest.127.2.643

24. Yoon NB, Son C, Um SJ. Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia. *Ann Lab Med.* (2013) 33:105–10. doi: 10.3343/alm.2013.33.2.105

25. Martens GW, Vallerskog T, Kornfeld H. Hypercholesterolemic LDL receptor-deficient mice mount a neutrophilic response to tuberculosis despite the timely expression of protective immunity. *J Leukoc Biol.* (2012) 91:849–57. doi: 10.1189/jlb.031164

26. Martens GW, Arikian C, Lee J, Ren F, Vallerskog T, Kornfeld H. Hypercholesterolemia impairs immunity to tuberculosis. *Infect Immun.* (2008) 76:464–72. doi: 10.1128/IAI.00037-08

27. Ettinger WH, Harris T, Verdery RB, Tracy R, Koubra E. Evidence for inflammation as a hypocholesterolemia in older people. *J Am Geriatr Soc.* (1995) 43:624–6. doi: 10.1111/j.1532-5415.1995.tb07334.x

28. Tietge UJF, Maegaeus C, Lund-Katz S, Grass D, DeBeer FC, Rader DL. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and Apo-A1 in response to inflammation in human Apo-A1 transgenic mice. *Arterioscler Thromb Vasc Biol.* (2002) 22:1213–8. doi: 10.1161/01.ATV.0000023228.90866.29

29. Aart L, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A in metabolism of acute-phase HDL by macrophages. *Arterioscler Thromb Vasc Biol.* (2000) 20:763–72. doi: 10.1161/01.ATV.20.3.763

30. Qin K, Liao D fang, Tang CK. ATP-binding membrane transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. *Mol Med.* (2010) 16:438–49. doi: 10.2119/molmed.2010.00004

31. Masana L, Correig E, Ibarraitz D, Anor F, Arroyo JA, Jiroic C, et al. Low HDL and high triglycerides predict COVID-19 severity. *Sci Rep.* (2021) 11:7217. doi: 10.1038/s41598-021-86747-5

32. Begue F, Tanaka S, Mouktadi Z, Rondeau P, Veeren B, Diotel N, et al. Altered high-density lipoprotein composition and functions during severe COVID-19. *Sci Rep.* (2021) 11:2291. doi: 10.1038/s41598-021-81638-1

33. Li Y, Zhang Y, Lu R, Dai M, Shen M, Zhang J, et al. Lipid metabolism changes in patients with severe COVID-19. *Clin Chim Acta.* (2021) 517:66–73. doi: 10.1016/j.cca.2021.02.011

34. Van Halm VP, Nielen MMJ, Nurmonomed MT, Van Schaardenburg D, Reesink HW, Voosky AE, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. *Ann Rheum Dis.* (2007) 66:184–8. doi: 10.1136/ard.2006.051672

35. Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Total cholesterol and LDL levels decrease before rheumatoid arthritis. *Ann Rheum Dis.* (2010) 69:1310–4. doi: 10.1136/ard.2009.122374

36. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. *Clin Rheumatol.* (2007) 26:1495–8. doi: 10.1007/s10067-007-0553-9

37. Vrielings F, Ronacher K, Kleyhans L, van den Akker E, Walzl G, Ottenhoff THM, et al. Patients with concurrent tuberculosis and diabetes have a pro-atherogenic plasma lipid profile. *EBio Med.* (2018) 32:192–200. doi: 10.1016/j.ebiom.2018.05.011

38. Hanrahan CF, Golub JE, Mohapi L, Tshabangu N, Modisengyanie T, Chaisson RE, et al. Body mass index and risk of tuberculosis and death. *AIDS.* (2010) 24:1501–8. doi: 10.1097/QAD.0b013e28233a2aa4

39. Diktanas S, Vasiliauskiene E, Balunek D, Danila E, Celadetame I, Boreikate E, et al. Factors associated with persistent sputum positivity at the end of the second month of tuberculosis treatment in Lithuania. *Tuberc Respir Dis.* (2018) 81:233–40. doi: 10.1016/j.trd.2017.0996

40. Kornfeld H, Sahukar SB, Procter-Gray E, Kumar NP, West K, Kane K, et al. Impact of diabetes and low body mass index on tuberculosis treatment outcomes. *Clin Infect Dis.* (2020) 71:E392–8. doi: 10.1093/cid/ciaa054

41. Park HO, Kim SH, Moon SH, Byun JH, Kim JW, Lee CE, et al. Association between body mass index and sputum culture conversion among South Korean patients with multidrug resistant tuberculosis in a tuberculosis referral hospital. * Infect Chemother.* (2016) 48:317–23. doi: 10.3947/ic.2016.48.4.317

42. Anuradha R, Munisankar S, Bhoobra Y, Dolla C, Kumanar P, Babu S. High body mass index is associated with heightened systemic and mycobacterial antigen – specific pro-inflammatory cytokines in latent tuberculosis. *Tuberculosis.* (2016) 101:56–61. doi: 10.1016/j.tube.2016.08.004

43. Shaviya N, Budambula V, Webale MK, Were T. Circulating interferon-gamma levels are associated with low body weight in newly diagnosed Kenyan non-substance using tuberculosis individuals. *Interdiscip Perspect Infect Dis.* (2016) 2016:415364. doi: 10.1155/2016/415364

44. Kathamuthu GR, Sridhar R, Baskaran D, Babu S. Low body mass index has minimal impact on plasma levels of cytokines and chemokines in tuberculous lymphadenitis. *J Clin Tuberc Other Mycobact Dis.* (2020) 20:100163. doi: 10.1016/j.jctubd.2020.100163

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.